These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 37495516)
1. Protein phosphatase 6 regulates trametinib sensitivity, a mitogen-activated protein kinase kinase (MEK) inhibitor, by regulating MEK1/2-ERK1/2 signaling in canine melanoma cells. Yamamoto M; Fujiwara N J Vet Med Sci; 2023 Sep; 85(9):977-984. PubMed ID: 37495516 [TBL] [Abstract][Full Text] [Related]
2. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Cronise KE; Hernandez BG; Gustafson DL; Duval DL Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548 [TBL] [Abstract][Full Text] [Related]
3. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552 [TBL] [Abstract][Full Text] [Related]
4. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Hutchinson KE; Johnson DB; Johnson AS; Sanchez V; Kuba M; Lu P; Chen X; Kelley MC; Wang Q; Zhao Z; Kris M; Berger MF; Sosman JA; Pao W Oncotarget; 2015 Sep; 6(26):22348-60. PubMed ID: 26084293 [TBL] [Abstract][Full Text] [Related]
5. Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes. Adams DG; Coffee RL; Zhang H; Pelech S; Strack S; Wadzinski BE J Biol Chem; 2005 Dec; 280(52):42644-54. PubMed ID: 16239230 [TBL] [Abstract][Full Text] [Related]
6. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471 [TBL] [Abstract][Full Text] [Related]
7. Role of protein phosphatase 2A in mGluR5-regulated MEK/ERK phosphorylation in neurons. Mao L; Yang L; Arora A; Choe ES; Zhang G; Liu Z; Fibuch EE; Wang JQ J Biol Chem; 2005 Apr; 280(13):12602-10. PubMed ID: 15661743 [TBL] [Abstract][Full Text] [Related]
8. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma. Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569 [TBL] [Abstract][Full Text] [Related]
9. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Vaidhyanathan S; Mittapalli RK; Sarkaria JN; Elmquist WF Drug Metab Dispos; 2014 Aug; 42(8):1292-300. PubMed ID: 24875464 [TBL] [Abstract][Full Text] [Related]
10. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366 [TBL] [Abstract][Full Text] [Related]
11. Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells. Schramek H; Feifel E; Healy E; Pollack V J Biol Chem; 1997 Apr; 272(17):11426-33. PubMed ID: 9111053 [TBL] [Abstract][Full Text] [Related]
12. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547 [TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360 [TBL] [Abstract][Full Text] [Related]
14. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico. Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483 [TBL] [Abstract][Full Text] [Related]
15. p38 MAPK regulates phosphorylation of Bad via PP2A-dependent suppression of the MEK1/2-ERK1/2 survival pathway in TNF-alpha induced endothelial apoptosis. Grethe S; Pörn-Ares MI Cell Signal; 2006 Apr; 18(4):531-40. PubMed ID: 15972258 [TBL] [Abstract][Full Text] [Related]
16. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy. Tong Z; Singh G; Rainbow AJ Cancer Res; 2002 Oct; 62(19):5528-35. PubMed ID: 12359764 [TBL] [Abstract][Full Text] [Related]
17. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells. Sarközi R; Miller B; Pollack V; Feifel E; Mayer G; Sorokin A; Schramek H J Cell Physiol; 2007 Apr; 211(1):88-100. PubMed ID: 17131384 [TBL] [Abstract][Full Text] [Related]
18. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in Wu PK; Hong SK; Park JI Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184 [TBL] [Abstract][Full Text] [Related]
19. Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics. Urasaki Y; Fiscus RR; Le TT Sci Rep; 2018 Jul; 8(1):9991. PubMed ID: 29968772 [TBL] [Abstract][Full Text] [Related]
20. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Mhaidat NM; Zhang XD; Jiang CC; Hersey P Clin Cancer Res; 2007 Feb; 13(4):1308-14. PubMed ID: 17317842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]